Twitter Beğeni Hilesi

In the COMBINE-AF study, #biomarkers NTproBNP, hs-cTnT & GDF-15 improve #heartfailure risk assessment in #Afib! hs-cTnT is equally important as #NTproBNP for HF risk assessment bit.ly/3ySKhNR #ESCCongress #JACC Paul M Haller Robert Giugliano TIMI Study Group

#ESCCongress2024 **MATTERHORN Trial** RCT of mitral transcatheter edge-edge repair (mTEER) versus MV surgery in patients with HFrEF and at least moderate secondary MR A thread...

#ESCCongress2024 You can read lots more about the trial here: Shelley Wood (she/her) Mamas A. Mamas TCTMD tctmd.com/news/mitraclip…

🔥 📄 SEQUOIA-HCM 🔥 European Society of Cardiology #ESCCongress JACC Journals symptomatic oHCM aficamten vs placebo Improved KCCQ, 👇chest pain Led by T32 fellow, rising 🌟 Charles Sherrod Saint Luke's Mid America Heart Institute KCCQ guru and mentor John Spertus Editorial response by Nosheen Reza, MD

📌Mineralocorticoid Antagonism in #HeartFailure: Established & Emerging Therapeutic Role #StateOfTheArt #MRA #HF #JACCHF

Watch this discussion of ♦️ #FINEARTS trial in #HFmrEF & #HFpEF ♦️#FINEHEART metaanalysis of #CKM trials ♦️#metanalysis of all #MRA trials in #HF An overview of steroidal versus nonsteroidal MRAs, broad indications for MRAs, & evidence that will change guidelines‼️ #ESCCongress

Simultaneously presented at #ESCCongress and published Nature Portfolio with M. Louis Handoko Prof. dr. Marlies Schijven 🩺 Pim van der Harst Folkert Asselbergs HFAPresident Wilfried Mullens Andrew J Sauer MD Ami Bhatt, MD Shehab Anwer, MD Tor Biering-Sørensen, MD, MSc, MPH, PhD Ankeet S. Bhatt, MD, MBA scottdavidsolomon

Challenges of #implementing #ArtificialIntelligence technology in cardiology and the risks of #AI #bias in this week’s The Lancet Digital Health What’s AI bias? How does it arise & what are its harms? How can we prevent it? 1st author Ariana Mihan MD student authors.elsevier.com/sd/article/S25…

New in #JACCHF: REVIVED-BCIS2 showed PCI in addition to #GDMT in #ICM did not improve health status beyond 6 months compared with #GDMT alone. PCI should not be recommended for all ICM. jacc.org/doi/10.1016/j.… Editorial: jacc.org/doi/10.1016/j.…

Future sniper. #DadJob

In 1 month we unveil special issue Journal of Cardiac Failure on interv heart failure! By Jennifer Rymer and me 😃 28 papers - 9 original studies, 6 state of art reviews, 7 editorials, 4 perspectives & more. 60 total submissions! 🙏🏽 to authors & Anu Lala-Trindade Robert Mentz, MD for faith in 2 plumbers!

This 👇🏽👇🏽👇🏽 Interventional & HF 🤝 Journal of Cardiac Failure lucky to have Jennifer Rymer & Srihari S. Naidu, MD leading a very special focus issue. STAY TUNED. Lots of exciting stuff coming your way 😊🙌🏽 Robert Mentz, MD Andrew J Sauer MD Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Alexander Hajduczok, MD 🇺🇦🙏 Mamas A. Mamas Gregg W. Stone MD Dan Burkhoff MD PhD

DAPA-HF and DELIVER: Relative risk reductons across all ranges of ejection fraction but those recently discharged from a hospitalization derive higher absolute benefit. Start GDMT early !!!! #CardioTwitter #Cardiology #CardioEd

These results reveal important opportunities and specific targets for rural health equity interventions Rural Hospital Performance in Guideline-Recommended Ischemic Stroke Thrombolysis, Secondary Prevention, and Outcomes ahajournals.org/doi/10.1161/ST… Shumei Man AHA Research

‼️ read this invited review‼️. The change in 🫀 allocation policy in 2018 has dramatically impacted the landscape of the field The Annals of Thoracic Surgery Bridge to Transplantation: Policies Impact Practices - The Annals of Thoracic Surgery annalsthoracicsurgery.org/article/S0003-…

🔴 From Hospital to Home: Evidence-Based Care for Worsening Heart Failure JACC Journals #CardioEd #Cardiology #CardioTwitter

Super review on mineralocorticoid receptor antagonists and the evidence to support their use in #heartfailure across the #LVEF continuum Andrew J Sauer MD jacc.org/doi/10.1016/j.… #MRA #steroidalMRA #nonsteroidalMRA

After the definition of pulmonary hypertension was changed, many patients with HF and group 2 PH meet the hemodynamic criteria of PAH (PAP>20, PVR>2) and can be misclassified. We studied patients with CardioMEMS and found that 1) PH is extremely prevalent at>85% and 2) 16% of

HFSA announces late-breaking research for 2024 annual meeting Check out: HuMAIN, FINEARTS, STEP HFpEF And I’ll be presenting CARE-HK in HF ⁦Mikhail Kosiborod⁩ ⁦Steve Greene⁩ cardiovascularbusiness.com/topics/profess…